{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:14:12Z","timestamp":1793229252220,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Gen Psychiatry"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the overall long-term effectiveness of aripiprazole in patients with schizophrenia in a general psychiatric practice setting in Taiwan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a prospective, open-label, multicenter, post-market surveillance study in Taiwanese patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder requiring a switch in antipsychotic medication because current medication was not well tolerated and\/or clinical symptoms were not well controlled. Eligible patients were titrated to aripiprazole (5-30 mg\/day) over a 12-week switching phase, during which their previous medication was discontinued. Patients could then enter a 52-week, long-term treatment phase. Aripiprazole was flexibly dosed (5-30 mg\/day) at the discretion of the treating physicians. Efficacy was assessed using the Clinical Global Impression scale Improvement (CGI-I) score, the Clinical Global Impression scale Severity (CGI-S) score, The Brief Psychiatry Rating Scale (BPRS), and the Quality of Life (QOL) scale, as well as Preference of Medicine (POM) ratings by patients and caregivers. Safety and tolerability were also assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 245 patients were enrolled and switched from their prior antipsychotic medications, and 153 patients entered the 52-week extension phase. In all, 79 patients (32.2%) completed the study. At week 64, the mean CGI-I score was 3.10 and 64.6% of patients who showed response. Compared to baseline, scores of CGI-S, QOL, and BPRS after 64 weeks of treatment also showed significant improvements. At week 12, 65.4% of subjects and 58.9% of caregivers rated aripiprazole as better than the prestudy medication on the POM. The most frequently reported adverse events (AEs) were headache, auditory hallucinations and insomnia. A total of 13 patients (5.3%) discontinued treatment due to AEs. No statistically significant changes were noted with respect to fasting plasma glucose, lipid profile, body weight, and body mass index after long-term treatment with aripiprazole.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although the discontinuation rate was high, aripiprazole was found to be effective, safe and well tolerated in the long-term treatment of Taiwanese patients with schizophrenia who continued to receive treatment for 64 weeks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1744-859x-9-35","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T18:14:02Z","timestamp":1284747242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting"],"prefix":"10.1186","volume":"9","author":[{"given":"Ming-Hong","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Tsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kao-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Ying","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Jui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsiu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Jen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,17]]},"reference":[{"key":"1037_CR1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"1037_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1176\/appi.ps.56.3.273","volume":"56","author":"HA Nasrallah","year":"2005","unstructured":"Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R: Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005, 56: 273-282. 10.1176\/appi.ps.56.3.273.","journal-title":"Psychiatr Serv"},{"key":"1037_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"American Psychiatric Association","year":"2004","unstructured":"American Psychiatric Association: Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry. 2004, 161: 1-56. 10.1176\/appi.ajp.161.1.1. 2","journal-title":"Am J Psychiatry"},{"key":"1037_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002, 302: 381-389. 10.1124\/jpet.102.033175.","journal-title":"J Pharmacol Exp Ther"},{"key":"1037_CR5","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 2003, 28: 1400-1411. 10.1038\/sj.npp.1300203.","journal-title":"Neuropsychopharmacol"},{"key":"1037_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejphar.2003.10.025","volume":"483","author":"S Jordan","year":"2004","unstructured":"Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004, 483: 45-53. 10.1016\/j.ejphar.2003.10.025.","journal-title":"Eur J Pharmacol"},{"key":"1037_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002, 441: 137-140. 10.1016\/S0014-2999(02)01532-7.","journal-title":"Eur J Pharmacol"},{"key":"1037_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/026988110401800308","volume":"18","author":"T Hirose","year":"2004","unstructured":"Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T: Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004, 18: 375-383. 10.1177\/026988110401800308.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 18","key":"1037_CR9","first-page":"47","volume":"65","author":"RD McQuade","year":"2004","unstructured":"McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH: A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004, 65 (Suppl 18): 47-56.","journal-title":"J Clin Psychiatry"},{"key":"1037_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","volume":"18","author":"JA Lieberman","year":"2004","unstructured":"Lieberman JA: Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004, 18: 251-267. 10.2165\/00023210-200418040-00005.","journal-title":"CNS Drugs"},{"key":"1037_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002, 63: 763-771.","journal-title":"J Clin Psychiatry"},{"key":"1037_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003, 60: 681-690. 10.1001\/archpsyc.60.7.681.","journal-title":"Arch Gen Psychiatry"},{"key":"1037_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","volume":"61","author":"SR Marder","year":"2003","unstructured":"Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003, 61: 123-136. 10.1016\/S0920-9964(03)00050-1.","journal-title":"Schizophr Res"},{"issue":"11","key":"1037_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","volume":"41","author":"J McEvoy","year":"2007","unstructured":"McEvoy J, Daniel D, Carson WJ, McQuade R, Marcus R: A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007, 41 (11): 895-905. 10.1016\/j.jpsychires.2007.05.002.","journal-title":"J Psychiatr Res"},{"key":"1037_CR15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S1092852900014784","volume":"11","author":"A Cutler","year":"2006","unstructured":"Cutler A, Marcus R, Hardy S, O'Donnell A, Carson B, McQuade B: The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectrums. 2006, 11: 691-702.","journal-title":"CNS Spectrums"},{"key":"1037_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S1461145703003651","volume":"6","author":"S Kasper","year":"2003","unstructured":"Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T: Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003, 6: 325-337. 10.1017\/S1461145703003651.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1037_CR17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","volume":"64","author":"TA Pigott","year":"2003","unstructured":"Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG: Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003, 64: 1048-1056. 10.4088\/JCP.v64n0910.","journal-title":"J Clin Psychiatry"},{"key":"1037_CR18","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare Publication (ADM) 76-338","author":"W Guy","year":"1976","unstructured":"Guy W: Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare Publication (ADM) 76-338. 1976, Rockville, MD: National Institute of Mental Health, 218-222."},{"key":"1037_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep. 1962, 10: 799-812. 10.2466\/PR0.10.3.799-812.","journal-title":"Psychol Rep"},{"key":"1037_CR20","volume-title":"WHOQoL Study Protocol. WHO (MNH7PSF\/93.9)","author":"World Health Organization","year":"1993","unstructured":"World Health Organization: WHOQoL Study Protocol. WHO (MNH7PSF\/93.9). 1993, Geneva, Switzerland: WHO"},{"key":"1037_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","volume":"84","author":"R Tandon","year":"2006","unstructured":"Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT: A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res. 2006, 84: 77-89. 10.1016\/j.schres.2005.12.857.","journal-title":"Schizophr Res"},{"key":"1037_CR22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2165\/00019053-200018020-00002","volume":"18","author":"E Lindstrom","year":"2000","unstructured":"Lindstrom E, Bingefors K: Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics. 2000, 18: 106-124.","journal-title":"Pharmacoeconomics"},{"key":"1037_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","volume":"65","author":"WW Fleischhacker","year":"2009","unstructured":"Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH: A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009, 65: 510-517. 10.1016\/j.biopsych.2008.07.033.","journal-title":"Biol Psychiatry"},{"key":"1037_CR24","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1185\/030079907X225448","volume":"23","author":"J Wolf","year":"2007","unstructured":"Wolf J, Janssen F, Lublin H, Salokangas RK, Allain H, Smeraldi E, Bernardo M, Millar H, Pans M, Adelbrecht C, Laughton J, Werner C, Maier W: A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin. 2007, 23: 2313-2323. 10.1185\/030079907X225448.","journal-title":"Curr Med Res Opin"},{"key":"1037_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","volume":"22","author":"R Kerwin","year":"2007","unstructured":"Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN: A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007, 22: 433-443. 10.1016\/j.eurpsy.2007.03.002.","journal-title":"Eur Psychiatry"},{"key":"1037_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity","year":"2004","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care. 2004, 27: 596-601. 10.2337\/diacare.27.2.596.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1037_CR27","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19 (Suppl 1): 1-93.","journal-title":"CNS Drugs"},{"key":"1037_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/schbul\/sbl037","volume":"33","author":"M De Hert","year":"2007","unstructured":"De Hert M, Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Peuskens J: A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull. 2007, 33: 823-830. 10.1093\/schbul\/sbl037.","journal-title":"Schizophr Bull"},{"key":"1037_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","volume":"27","author":"M Byerly","year":"2007","unstructured":"Byerly M, Suppes T, Tran QV, Baker RA: Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007, 27: 639-661. 10.1097\/jcp.0b013e31815ac4e5.","journal-title":"J Clin Psychopharmacol"},{"key":"1037_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.4088\/JCP.v68n0808","volume":"68","author":"YM Bai","year":"2007","unstructured":"Bai YM, Ting Chen T, Chen JY, Chang WH, Wu B, Hung CH, Kuo Lin W: Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007, 68: 1218-1225. 10.4088\/JCP.v68n0808.","journal-title":"J Clin Psychiatry"}],"container-title":["Annals of General Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1744-859X-9-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:16:35Z","timestamp":1630469795000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals-general-psychiatry.biomedcentral.com\/articles\/10.1186\/1744-859X-9-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1186\/1744-859x-9-35","relation":{},"ISSN":["1744-859X"],"issn-type":[{"value":"1744-859X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,17]]},"assertion":[{"value":"8 March 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}